149 related articles for article (PubMed ID: 8447355)
21. Lipid metabolism effects with desogestrel-containing oral contraceptives.
Burkman RT
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1033-40. PubMed ID: 8447357
[TBL] [Abstract][Full Text] [Related]
22. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
Hümpel M; Täuber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B; Seifert W; Schütt B
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
[TBL] [Abstract][Full Text] [Related]
23. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.
Kuhnz W; Pfeffer M; al-Yacoub G
J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
Kuhnz W
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2120-7. PubMed ID: 2124087
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
26. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
Nader S; Riad-Gabriel MG; Saad MF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
[TBL] [Abstract][Full Text] [Related]
27. Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease.
Di Lieto A; De Rosa G; Albano G; Pagnano AM; Campanile M; Terracciano L; Pontillo M; Cimmino E; Covelli A; Paladini A
Eur J Obstet Gynecol Reprod Biol; 1994 May; 55(1):71-83. PubMed ID: 7958144
[TBL] [Abstract][Full Text] [Related]
28. The effects on hemostasis of oral contraceptives containing desogestrel.
Stubblefield PG
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
[TBL] [Abstract][Full Text] [Related]
29. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives.
Kloosterboer HJ; Vonk-Noordegraaf CA; Turpijn EW
Contraception; 1988 Sep; 38(3):325-32. PubMed ID: 3139361
[TBL] [Abstract][Full Text] [Related]
30. Effects of desogestrel on carbohydrate metabolism.
Shoupe D
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
[TBL] [Abstract][Full Text] [Related]
31. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
Palatsi R; Reinilä M; Kivinén S
Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of gestagens: some problems.
Fotherby K
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):323-8. PubMed ID: 2115297
[TBL] [Abstract][Full Text] [Related]
33. Prodrug versus drug effects of 150 micrograms desogestrel or 3-keto-desogestrel in combination with 30 micrograms ethinylestradiol on hormonal parameters: relevance of the peak serum level of 3-keto-desogestrel.
Kuhl H; Jung-Hoffmann C; Fitzner M
Horm Res; 1995; 44(3):126-32. PubMed ID: 7590643
[TBL] [Abstract][Full Text] [Related]
34. Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels.
Nilsson B; von Schoultz B
Gynecol Obstet Invest; 1989; 27(3):151-4. PubMed ID: 2525511
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel.
Orme M; Back DJ; Ward S; Green S
Contraception; 1991 Apr; 43(4):305-16. PubMed ID: 1830266
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays.
Fuhrmann U; Slater EP; Fritzemeier KH
Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284
[TBL] [Abstract][Full Text] [Related]
37. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
38. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications.
Goldzieher JW
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):318-22. PubMed ID: 2196804
[TBL] [Abstract][Full Text] [Related]
39. Clinical results with subcutaneous implants containing 3-keto desogestrel.
Olsson SE; Odlind V; Johansson E
Contraception; 1990 Jul; 42(1):1-11. PubMed ID: 2117514
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
Phillips A; Hahn DW; McGuire JL
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
